The company is currently at CFP on operations with existing products and with Isradipine dropping as their next drug launch.....which should get the company CFP on operations and R&D costs.....why in world would the company risk a RS prior to that? Makes absolutely no sense. The company will do best to put out their twice daily oxy/nal product and then look at matters regarding their share count six months down the road post twice daily launch IMO.
News 
Market Data 
Discover 
